Form 4: Natera President Sells Shares for Tax Obligations

Solomon Moshkevich, President of Clinical Diagnostics at Natera, sold 2,182 shares to cover tax liabilities resulting from the vesting of restricted stock units.

Summary

• Solomon Moshkevich sold a total of 2,182 shares of Natera common stock on April 27, 2026.
• The transactions were executed in two separate blocks at prices of $203.75 and $204.39 per share.
• The total value of the shares sold is approximately $445,340.90.
• These sales were non-discretionary and were conducted specifically to satisfy tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs).
• Following the transactions, Moshkevich continues to hold 145,700 shares of the company directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine tax-related sale that does not reflect a change in management's outlook on the company's valuation.

Positives

• The reporting person maintains a very large equity position of 145,700 shares, showing significant skin in the game.
• Sales were mandated by tax obligations rather than a discretionary decision to exit the position.
• Transactions were made under a Rule 10b5-1(c) plan, providing an affirmative defense against insider trading concerns.

Negatives

• Insider selling, regardless of the reason, reduces the total direct ownership of a key executive.
• The sale price of approximately $204 represents the benchmark at which the executive liquidated a portion of their holdings.

Risks

• No specific business or operational risks are disclosed in this ownership change filing.

Future Outlook

The filing indicates that future sales may occur as RSUs continue to vest, provided they are governed by the existing 10b5-1 plan for tax purposes.

Management Comments

• The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard administrative procedures in the genetic testing and biotechnology sectors, where equity-based compensation is a primary component of executive pay.

Comparison to Industry Standards

• Natera's use of Rule 10b5-1 plans for tax-related sales is consistent with practices at peers such as Guardant Health and Exact Sciences.
• The executive's retention of over 98% of their total holdings following this vest-and-sell event is a positive signal compared to more aggressive insider liquidations.

Related Party Transactions

• The reporting person, an officer of the company, sold shares back to the open market to cover tax obligations.

Stakeholder Impact

• Minimal impact on shareholders as the volume of shares sold is negligible compared to the total shares outstanding and the executive's remaining stake.

Next Steps

• Monitor future Form 4 filings for additional RSU vesting events and associated tax-related sales.

Key Dates

Recommendation

A hold recommendation is appropriate as this filing represents routine insider activity for tax purposes and does not provide new material information regarding the company's financial performance or strategic direction.

Keywords

Natera, NTRA, Insider Selling, Solomon Moshkevich, Clinical Diagnostics, Restricted Stock Units, Rule 10b5-1, Tax Withholding